Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  protein tyrosine kinase >  ARRY-380

ARRY-380

Basic information Safety Supplier Related

ARRY-380 Basic information

Product Name:
ARRY-380
Synonyms:
  • ARRY-380 (analog )
  • Arry-830
  • ARRY-380;ARRY380; ARRY 380
  • 6-[5-[[[2-(Methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]
  • Arry-380, >=98%
  • ARRY-380
  • 6-[5-[[[2-(Methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4-quinazolinamine
  • HER2-Inhibitor-1
CAS:
937265-83-3
MF:
C29H27N7O4S
MW:
569.63
EINECS:
813-083-0
Product Categories:
  • Inhibitors
  • Aromatics
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Sulfur & Selenium Compounds
Mol File:
937265-83-3.mol
More
Less

ARRY-380 Chemical Properties

Density 
1.43
storage temp. 
Store at -20°C
solubility 
≥28.5 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
form 
solid
pka
6.34±0.19(Predicted)
More
Less

ARRY-380 Usage And Synthesis

Description

Arry-380 analog was designed as an inhibitor of EGFR (ErbB1).

Uses

ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM and also inhibits EGFR with IC50 of 4 μM.

Uses

Labelled ARRY-380. ARRY-380 is an orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2.

target

p95-HER2

References

[1] s. l. moulder, v. borges, s. k. l. chia, t. baetz, e. barrett, j. garrus, k. guthrie, c. kass, e. laird, j. lyssikatos, f. marmsater, e. wallace. arry-380, a selective her2 inhibitor: from drug design to clinical evaluation. poster of aacr-nci-eortc, nov 12-16, 2011, san francisco, ca.
[2] victoria dinkel, deborah anderson, shannon winski, jim winkler, kevin koch and patrice lee. arry-380, a potent, small molecule inhibitor of erbb2, increases survival in intracranial erbb2+ xenograft models in mice. poster available at www.arraybiopharma.com
[3] s. chia, t. baetz, s. d'aloisio, g. fernetich, b. freeman, e. barrett, c. kass, j. kang, b. sajan, s. moulder, and j. garrus. a phase 1 study to assess the safety, tolerability and pharmacokinetics of arry-380 – an oral inhibitor of her2. cancer res 2009;69(24 suppl):abstract nr 5111.

ARRY-380Supplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Chembest Research Laboratories Limited
Tel
021-20908456
Email
sales@BioChemBest.com
Chemsky (shanghai) International Co.,Ltd
Tel
021-50135380
Email
shchemsky@sina.com
Jinan Trio PharmaTech Co., Ltd.
Tel
+86 (531) 88811783
Email
sales@trio-pharmatech.com (International market)
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
More
Less

ARRY-380(937265-83-3)Related Product Information